Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) rose 3.1% on Monday . The company traded as high as $1.8050 and last traded at $1.8050. 6,746 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 1,049,645 shares. The stock had previously closed at $1.75.
Virios Therapeutics Price Performance
The firm has a market capitalization of $34.76 million, a PE ratio of -6.69 and a beta of 1.58. The company has a fifty day moving average of $1.54 and a 200-day moving average of $2.09.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for fibrotic diseases. The company leverages its proprietary small-molecule platform to identify and advance compounds designed to modulate key pathways involved in scar formation and tissue repair. By concentrating on conditions with high unmet medical need, Virios aims to improve patient outcomes through more effective and safer treatment options.
The company’s lead development candidate, VTI-1002, is an oral small molecule inhibitor in clinical trials for the prevention and treatment of hypertrophic scars and keloids.
See Also
- Five stocks we like better than Virios Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
